Comprehensive Stock Comparison
Compare Catalyst Pharmaceuticals, Inc. (CPRX) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CPRX | 19.8% revenue growth vs REGN's 1.0% |
| Value | CPRX | Lower P/E (12.4x vs 17.3x), PEG 0.66 vs 2.73 |
| Quality / Margins | CPRX | 36.4% net margin vs REGN's 31.4% |
| Stability / Safety | REGN | Beta 0.58 vs CPRX's 0.82 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; CPRX pays no meaningful dividend |
| Momentum (1Y) | REGN | +12.4% vs CPRX's +0.8% |
| Efficiency (ROA) | CPRX | 19.4% ROA vs REGN's 11.1%, ROIC 83.9% vs 12.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Valuation efficiency (growth/$)
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases. It generates revenue primarily from sales of Firdapse — its amifampridine phosphate tablets for Lambert-Eaton myasthenic syndrome — which represents the vast majority of its income, supplemented by its pediatric LEMS drug Ruzurgi. The company's moat lies in its orphan drug exclusivity for rare disease treatments and its specialized expertise in neuromuscular disorders, creating high barriers to entry.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CPRX leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). REGN leads in 1 (Risk & Volatility).
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 24.4x CPRX's $589M. Profitability is closely matched — net margins range from 36.4% (CPRX) to 31.4% (REGN). On growth, CPRX holds the edge at +7.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CPRXCatalyst Pharmace… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $589M | $14.3B |
| EBITDAEarnings before interest/tax | $295M | $4.2B |
| Net IncomeAfter-tax profit | $214M | $4.5B |
| Free Cash FlowCash after capex | $209M | $3.2B |
| Gross MarginGross profit ÷ Revenue | +85.2% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +43.8% | +25.7% |
| Net MarginNet income ÷ Revenue | +36.4% | +31.4% |
| FCF MarginFCF ÷ Revenue | +35.4% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.6% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.1% | -2.5% |
Valuation Metrics
At 13.7x trailing earnings, CPRX trades at a 27% valuation discount to REGN's 18.8x P/E. Adjusting for growth (PEG ratio), CPRX offers better value at 0.73x vs REGN's 2.98x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | CPRXCatalyst Pharmace… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $2.8B | $107.6B |
| Enterprise ValueMkt cap + debt − cash | $2.1B | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | 13.74x | 18.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.36x | 17.25x |
| PEG RatioP/E ÷ EPS growth rate | 0.73x | 2.98x |
| EV / EBITDAEnterprise value multiple | 7.18x | 21.64x |
| Price / SalesMarket cap ÷ Revenue | 4.80x | 7.50x |
| Price / BookPrice ÷ Book value/share | 3.08x | 2.72x |
| Price / FCFMarket cap ÷ FCF | 13.55x | 26.36x |
Profitability & Efficiency
CPRX delivers a 22.5% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $14 for REGN. CPRX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to REGN's 0.09x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs CPRX's 4/9, reflecting strong financial health.
| Metric | CPRXCatalyst Pharmace… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | +22.5% | +14.4% |
| ROA (TTM)Return on assets | +19.4% | +11.1% |
| ROICReturn on invested capital | +83.9% | +12.4% |
| ROCEReturn on capital employed | +30.6% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 0.09x |
| Net DebtTotal debt minus cash | -$707M | -$16.2B |
| Cash & Equiv.Liquid assets | $709M | $18.9B |
| Total DebtShort + long-term debt | $2M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in CPRX five years ago would be worth $57,700 today (with dividends reinvested), compared to $16,977 for REGN. Over the past 12 months, REGN leads with a +12.4% total return vs CPRX's +0.8%. The 3-year compound annual growth rate (CAGR) favors CPRX at 14.8% vs REGN's 1.1% — a key indicator of consistent wealth creation.
| Metric | CPRXCatalyst Pharmace… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | -0.3% | +0.8% |
| 1-Year ReturnPast 12 months | +0.8% | +12.4% |
| 3-Year ReturnCumulative with dividends | +51.2% | +3.4% |
| 5-Year ReturnCumulative with dividends | +477.0% | +69.8% |
| 10-Year ReturnCumulative with dividends | +2098.1% | +104.7% |
| CAGR (3Y)Annualised 3-year return | +14.8% | +1.1% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than CPRX's 0.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.2% from its 52-week high vs CPRX's 86.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CPRXCatalyst Pharmace… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 0.58x |
| 52-Week HighHighest price in past year | $26.58 | $821.11 |
| 52-Week LowLowest price in past year | $19.05 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +86.8% | +95.2% |
| RSI (14)Momentum oscillator 0–100 | 57.9 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 976K | 687K |
Analyst Outlook
Wall Street rates CPRX as "Buy" and REGN as "Buy". Consensus price targets imply 43.0% upside for CPRX (target: $33) vs 9.7% for REGN (target: $857). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | CPRXCatalyst Pharmace… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.00 | $857.17 |
| # AnalystsCovering analysts | 16 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.9% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Catalyst Pharmaceut… (CPRX) | 100 | 568.18 | +468.2% |
| Regeneron Pharmaceu… (REGN) | 100 | 162.46 | +62.5% |
Catalyst Pharmaceut… (CPRX) returned +477% over 5 years vs Regeneron Pharmaceu… (REGN)'s +70%. A $10,000 investment in CPRX 5 years ago would be worth $57,700 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Catalyst Pharmaceut… (CPRX) | $0.00 | $589M | — |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Catalyst Pharmaceuticals, Inc.'s revenue grew from $0M (2016) to $589M (2025) — a 0.0% CAGR. Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Catalyst Pharmaceut… (CPRX) | -68.0% | 36.4% | +153.5% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Catalyst Pharmaceut… (CPRX) | 12.5 | 13.9 | +11.2% |
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Catalyst Pharmaceuticals, Inc. has traded in a 5x–27x P/E range over 7 years; current trailing P/E is ~14x. Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Catalyst Pharmaceut… (CPRX) | -0.22 | 1.68 | +863.6% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Catalyst Pharmaceuticals, Inc.'s EPS grew from $-0.22 (2016) to $1.68 (2025). Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
Catalyst Pharmaceuticals, Inc. generated $209M FCF in 2025 (+251% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
CPRX vs REGN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CPRX or REGN a better buy right now?
Catalyst Pharmaceuticals, Inc. (CPRX) offers the better valuation at 13.7x trailing P/E (12.4x forward), making it the more compelling value choice. Analysts rate Catalyst Pharmaceuticals, Inc. (CPRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CPRX or REGN?
On trailing P/E, Catalyst Pharmaceuticals, Inc. (CPRX) is the cheapest at 13.7x versus Regeneron Pharmaceuticals, Inc. at 18.8x. On forward P/E, Catalyst Pharmaceuticals, Inc. is actually cheaper at 12.4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Catalyst Pharmaceuticals, Inc. wins at 0.66x versus Regeneron Pharmaceuticals, Inc.'s 2.73x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CPRX or REGN?
Over the past 5 years, Catalyst Pharmaceuticals, Inc. (CPRX) delivered a total return of +477.0%, compared to +69.8% for Regeneron Pharmaceuticals, Inc. (REGN). A $10,000 investment in CPRX five years ago would be worth approximately $58K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CPRX returned +21.0% versus REGN's +104.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CPRX or REGN?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus Catalyst Pharmaceuticals, Inc.'s 0.82β — meaning CPRX is approximately 42% more volatile than REGN relative to the S&P 500. On balance sheet safety, Catalyst Pharmaceuticals, Inc. (CPRX) carries a lower debt/equity ratio of 0% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — CPRX or REGN?
Catalyst Pharmaceuticals, Inc. (CPRX) is the more profitable company, earning 36.4% net margin versus 31.4% for Regeneron Pharmaceuticals, Inc. — meaning it keeps 36.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPRX leads at 43.8% versus 25.7% for REGN. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CPRX or REGN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Catalyst Pharmaceuticals, Inc. (CPRX) is the more undervalued stock at a PEG of 0.66x versus Regeneron Pharmaceuticals, Inc.'s 2.73x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Catalyst Pharmaceuticals, Inc. (CPRX) trades at 12.4x forward P/E versus 17.3x for Regeneron Pharmaceuticals, Inc. — 4.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CPRX: 43.0% to $33.00.
07Which pays a better dividend — CPRX or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. CPRX does not pay a meaningful dividend and should not be held primarily for income.
08Is CPRX or REGN better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58), +104.7% 10Y return). Both have compounded well over 10 years (REGN: +104.7%, CPRX: +21.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CPRX and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: CPRX is a small-cap deep-value stock; REGN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.